3Spine Gains IDE Approval for Clinical Trial

3Spine announced FDA Investigational Device Exemption (IDE) approval for their U.S. pivotal clinical trial. The company previously completed contracting and site initiation at 16 U.S. centers for a prospective real-world evidence (RWE) fusion study, which has been enrolling since May 2021. As sites complete enrollment of their RWE cohort, each...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us